Selected Grants
NCI National Clinical Trials Network (UG1)
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2026A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
Clinical TrialPrincipal Investigator · Awarded by Clinipace, Inc. · 2016 - 2026Phase Ib Study of MEM-288 Oncolytic Virus in Combination with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
ResearchCo-Mentor · Awarded by Bristol-Myers Squibb Foundation · 2023 - 2026Alliance NCTN/NCORP DoD
Clinical TrialPrincipal Investigator · Awarded by Alliance NCTN Foundation · 2020 - 2025Alliance/NCORP Parent - Non Federal
Clinical TrialPrincipal Investigator · Awarded by Alliance NCTN Foundation · 2020 - 2025Alliance/NCORP Parent - Federal
Clinical TrialPrincipal Investigator · Awarded by Alliance NCTN Foundation · 2020 - 2025A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Durvalumab plus Chemotherapy Prior to Surgery Followed by Durvalumab Post-surgery Versus Placebo plus Chemotherapy Prior to Surgery Followed by Placebo Post surgery
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2019 - 2024Alliance ICARE Data Project - Project Order #5 SmartForm Implementation
ResearchPrincipal Investigator · Awarded by Alliance Data Innovation Lab, LLC · 2024 - 2024Alliance ICARE Data Project - Project Order #2
ResearchPrincipal Investigator · Awarded by Alliance Data Innovation Lab, LLC · 2022 - 2024Alliance ICARE Data Project - Project Order #1
ResearchPrincipal Investigator · Awarded by Alliance Data Innovation Lab, LLC · 2022 - 2024A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB Pfizer C3651003
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2023 - 2024PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANAMORELIN HCL
Clinical TrialPrincipal Investigator · Awarded by Helsinn Healthcare S.A. · 2019 - 2024A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2020 - 2023A Phase 1b, 12-Week, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Repeated Subcutaneous Administrations of PF-06946860 In Patients with Non-Small Cell Lung Cancer and Cachexia
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2020 - 2023A phase II, Open-label, single-arm study to assess the safety and efficacy of AZD9291 in patients with locally advanced/mteastatic non-small cell lung cancer whose disease has progressed with previous epidermal growth factor receptor
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2014 - 2022NCI National Clinical Trials Network U10 (Year 5)
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2019Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer
ResearchSignificant Contributor · Awarded by V Foundation for Cancer Research · 2016 - 2018Phase II anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma
Clinical TrialPrincipal Investigator · Awarded by Bayer HealthCare AG · 2016 - 2018EMD Serono, Inc. Education Event
ConferencePrincipal Investigator · Awarded by EMD Serono Inc · 2017 - 2017TIGER 1: A randomized, open-label, phase II study of CO-1686 or Erlotinib as first-line treatment of patients with EGFR-Mutant advanced non-small cell lung cancer
Clinical TrialPrincipal Investigator · Awarded by Clovis Oncology, Inc. · 2015 - 2017A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in Second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma
Clinical TrialPrincipal Investigator · Awarded by MedImmune, Inc. · 2013 - 2017A phase III, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of selumetinib (AZD624; ARRY-142886) Hyd-Sulfate) in combination with Docetaxel, in patients receiving second line treatment for KRAS Mutation-Positive
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2014 - 2016FibroGen, Inc. FGCL-3019-073, Phase 2, a Trial of FG 3019 Monotherapy as Neoadjuvant Treatment in Subjects with Stage I-II Squamous Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Fibrogen, Inc. · 2015 - 2016A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
Clinical TrialPrincipal Investigator · Awarded by Morphotek, Inc · 2016 - 2016A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC
Clinical TrialPrincipal Investigator · Awarded by University of Virginia - Charlottesville · 2012 - 2015Clinical Oncology Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015ANC Study Group
ResearchPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2014 - 2014Cancer and Leukemia Group B
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2014Research Training in Cancer Biology and Therapy
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1978 - 2013Refining and Validating Genomic Signatures in Lung Cancer
ResearchCollaborator · Awarded by National Institutes of Health · 2009 - 2010Prospective Validation of Genomic Signatures of Chemosensitivity in NSCLC
ResearchCollaborator · Awarded by National Institutes of Health · 2009 - 2010Biomarker Studies for Novel Anti-Cancer Agents
ResearchConsultant · Awarded by National Institutes of Health · 2003 - 2008Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers
ResearchCo Investigator · Awarded by National Institutes of Health · 2002 - 2007Measurement of Hypoxia in Non-Small Cell Lung Carcinoma
ResearchInvestigator · Awarded by National Institutes of Health · 2002 - 2006Dexasome Based Immunotherapy of Lung Cancer
ResearchCollaborator · Awarded by National Institutes of Health · 2001 - 2004Same
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1998 - 2003Cancer and Leukemia Group B
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 2003Cancer and Leukemia Group B
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 2003Using Plasma TGFB1 Levels to Escalate Radiotherapy Doses
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2000 - 2003Comprehensive Cancer Center Core Support Grant
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1976 - 1998Comprehensive Cancer Center Core Support Grant
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1976 - 1998Cancer Center Core Support Grant
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 1976 - 1998Cancer And Leukemia Group B
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1998Cancer And Leukemia Group B
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 1998Cancer And Leukemia Group B
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1988 - 1998External Relationships
- Actimed
- BioAtla
- Changchun Gene Science Pharmaceuticals
- G1 Therapeutics, Inc.
- Pfizer Inc.
- Tensegrity Pharma
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.